Epigenetics

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

Retrieved on: 
星期五, 五月 10, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Taste, LNP, Cell, Liver, AAV, Safety, Hepatocyte, Engineering, Gene, CNS, Eye, XE, Society, CRISPR, Epigenetics, Annual general meeting, Vaccine

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.

Key Points: 
  • Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.
  • The data described in the company’s oral presentations and poster session showcase the dramatic potency, safety, and specificity of the novel XE genome editing and ELXR epigenetic editing platforms and the company's developments in successfully advancing these technologies into large animal models, including non-human primates.
  • “A major challenge in the field has been to achieve saturating levels of genome editing, at therapeutically relevant doses, with molecules that have better safety and delivery characteristics than CRISPR-Cas9—this has not been possible to date,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe.
  • “For the first time, Scribe has demonstrated that the holistic engineering of a wholly unique and highly potent CRISPR enzyme can enable this goal.

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
星期一, 四月 22, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, XE, CRISPR, Epigenetics, Cell, Gene, Society, Annual general meeting, Baltimore Convention Center

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.

Key Points: 
  • Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.
  • Scribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach.
  • The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.

Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus

Retrieved on: 
星期一, 十一月 13, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Clinical Trials, Hepatology, DNA, Therapy, Hepatitis B virus, AASLD, Tune, HBV, Multimedia, Patient, TEMPO, CccDNA, Genome, Standard of care, University, Epigenetics, SOC, Vaccine, Medicine, Boston

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.

Key Points: 
  • Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.
  • (Graphic: Business Wire)
    The Tune HBV program was unveiled by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on Hepatitis B Virus (HBV) at the American Association for the Study of Liver Diseases ( AASLD ) conference in Boston, MA on November 11th.
  • As Tune Therapeutics’ Chief Scientific Officer Derek Jantz elucidates, this fact was the crucial driver for a new therapeutic approach using TEMPO.
  • “We can leverage the same, exact mechanism of virus control that we observe in these functionally-cured patients by switching off the virus using a targeted epigenetic silencer.

Brain Aneurysm Foundation Announces 2023 Research Grants

Retrieved on: 
星期四, 九月 21, 2023
Subarachnoid hemorrhage, Bleeding, Therapy, Beth Israel Deaconess Medical Center, Education, Genetics, Prevalence, Blood, Epigenetics, Impact, Aneurysm, Stroke, Policy, Kick, Aortic rupture, Skull, Research, Risk, Brain, Biomarker, Pop, Science, SAH, ZIC3, BAF, Rupture, Robotics, HDAC2, Big data, Biology, Effectiveness, Diagnosis, Ecosystem, Role, Comparative effectiveness research, Health, Headache, Woman, Social media, Disease, Pharmaceutical industry, Mouse, Engagement

HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.

Key Points: 
  • Provides Funding for 17 Research Efforts that aim to Address the Underlying Causes of Disease, New Treatment Paradigms and Key Markers of Ruptures and Hemorrhage
    Total Annual Research Funding Eclipses $5 million; BAF Kicks off its Annual Day of Engagement to Support its Mission of Reducing the Prevalence and Impact of Brain Aneurysms
    HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.
  • Research grants are a cornerstone of the organization's mission, as it works to fund critical advances at a time where Federal dollars for brain aneurysm research amounts to just over $2 for every person afflicted.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

Icahn School of Medicine at Mount Sinai Licenses Next-Generation Diagnostic Test Epigenetic /AI Platform to GNOMX Corp.

Retrieved on: 
星期一, 九月 18, 2023
Infection, Yale School of Medicine, Business development, DARPA, University, Lyme disease, Planetary Observer program, ECHO, Prognosis, Research, COVID, University of Pittsburgh School of Medicine, Department of Neurology, Xuanwu hospital, Doctor of Philosophy, Princeton University, Icahn School of Medicine at Mount Sinai, Sepsis, MSIP, Patient, Artificial intelligence, Diagnosis, Policy, Health, Mount Sinai Health System, Wilfrid Sellars, Epigenetics, Gene, Vaccine, Pharmaceutical industry, Management, MD, Neurology, Medicine

NEW YORK, Sept. 18, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.

Key Points: 
  • The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
  • NEW YORK, Sept. 18, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
  • The GNOMX epigenetic diagnostic platform includes technology developed by Mount Sinai faculty and was optioned by Mount Sinai to GNOMX.
  • Mount Sinai and Mount Sinai faculty, including Dr. Sealfon, have a financial interest in this technology and in GNOMX pursuant to the Mount Sinai Intellectual Property Policy.

City of Hope diabetes experts present new research on beta cells, insulin secretion and islet transplantation at annual American Diabetes Association (ADA) Conference

Retrieved on: 
星期二, 六月 27, 2023
Ruth B., Insulin resistance, City of Hope, Failure, Life, Drug discovery, Mitochondrion, Survival, Glucagon, Science, Metabolism, Patient, American Diabetes Association, ADA, AKT1, Conditional sentence, City of Hope National Medical Center, Endocrine & Metabolism Research Institute, Ageing, Epigenetics, Research, Overnutrition, Liver, DNA, Insulin, Cancer, Cell, Transplant, LOS, Therapy, Translation, Molecule, Arthur, Glucose, Clinical trial, Nutrient, Quality of life, Genomics, Inflammation, Proteomics, Metabolomics, Endocrinology, Gene, Medical device, Pharmaceutical industry, Phosphorus, Antibiotics, Dietary supplement, Dentistry, Hope, City, Diabetes

City of Hope diabetes scientists presented research at American Diabetes Association conference.

Key Points: 
  • City of Hope diabetes scientists presented research at American Diabetes Association conference.
  • Sangeeta Dhawan, Ph.D. , an associate professor in City of Hope's Department of Translational Research & Cellular Therapeutics , discussed epigenetic control of beta cell stress response and senescence.
  • Recent research by Dhawan and members of her lab outlined novel findings identifying the mechanisms by which cellular stress causes senescence.
  • Islet transplantation involves isolating insulin producing cells from a donated pancreas and infusing them into a patient with diabetes.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
星期三, 五月 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.

Turn Biotechnologies Shows Promise of Epigenetic Reprogramming to Rejuvenate Skin at SEASON Aesthetic Conference

Retrieved on: 
星期一, 五月 1, 2023
Maintenance, Bio, Stem cell, Biotechnology, Research, Cosmetic, Messenger, ERA, Patient, Extracellular matrix, Faculty, ECM, Epigenetics, George Washington University, Conference, Skin, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
  • The data discussed at SEASON Aesthetic Conference showed that Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology reprograms cells within the extracellular matrix (ECM), resulting in a broad panel of changes related to improved skin quality and structure.
  • Research demonstrates that Turn Bio's cellular data in-vitro has translated to the tissue level ex-vivo.
  • Dr. Hsia, who has worked in biotechnology for nearly 20 years, was gratified by the experience of presenting to SEASON attendees.

Kristin Kaelber MD, PhD to Speak on "Food as Medicine" at the 12th Annual Heart and Science of Yoga Physician CME Conference October 17-21, 2023

Retrieved on: 
星期二, 四月 25, 2023
CME, Science, Food, University, Pediatrics, Health, Lifestyle medicine, Digestion, Himalayan Institute of Yoga Science and Philosophy, Teaching, FACP, Heart, Curriculum, University Hospitals Cleveland Medical Center, American Meditation Institute, Holism, American Medical Association, Public key certificate, Addiction medicine, FAAP, Student, Meditation, Patient, Physician, Eating, Population health, Internal medicine, AMI, Faculty, Case Western Reserve University School of Medicine, American College, Medical education, Critical Care Medicine (journal), Nursing, Medicine, Epigenetics, Rheumatology, Doctor of Philosophy, MD, Yoga

AVERILL PARK, N.Y., April 25, 2023 /PRNewswire-PRWeb/ -- Internal Medicine physician Kristin Kaelber MD, PhD, FAAP, FACP will join the faculty of The American Meditation Institute (AMI) at the 12th annual Heart and Science of Yoga conference, October 17-21, 2023 at the Equinox Resort and Spa in Manchester, Vermont. Accredited for 32 CMEs, (34 for conference alumni), this comprehensive training in Yoga Science as Holistic Mind/Body Medicine is accredited through the American Medical Association, and designed to help identify, prevent and relieve stress and burnout currently being experienced by physicians and other healthcare professionals.

Key Points: 
  • AVERILL PARK, N.Y., April 25, 2023 /PRNewswire-PRWeb/ -- Internal Medicine physician Kristin Kaelber MD, PhD, FAAP, FACP will join the faculty of The American Meditation Institute (AMI) at the 12th annual Heart and Science of Yoga conference, October 17-21, 2023 at the Equinox Resort and Spa in Manchester, Vermont.
  • Presenter Kristin Kaelber MD, PhD, FAAP, FACP graduated from Case Western Reserve University School of Medicine, and is Board Certified in Internal Medicine and Pediatrics.
  • She serves as a member of the AMI Department of Medical Education and has been practicing Yoga Science as Holistic Mind/Body Medicine since 2015.
  • The entire "Heart and Science of Yoga" CME conference curriculum is dedicated to providing quality, comprehensive and evidence-based education to physicians and other health care providers on Yoga Science as holistic mind/body medicine.

Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress

Retrieved on: 
星期二, 四月 25, 2023
Congress, Cancer, Epigenetics, Disease, Doctor of Philosophy, Messenger, Vaccine, Pharmaceutical industry

MOUNTAIN VIEW, Calif., April 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, will discuss the potential of using epigenetic reprogramming to fight disease, including cancer.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 25, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, will discuss the potential of using epigenetic reprogramming to fight disease, including cancer.
  • Mustafa Turkoz, PhD, Turn Bio immunology, will share data showing the company has used its ERA™ (Epigenetic Reprogramming of Age) technology to enhance T cell performance against tumor cells.
  • The discussion will occur at the World Oncology Cell Therapy Congress being held April 25-26 in Boston.
  • The World Oncology Cell Therapy Congress is the only annual meeting that brings together drug developers, solution providers, and clinicians whose purpose is to deliver safe and effective adoptive cell therapy products to clinical implementation.